Study participants were randomly assigned 2:1 to receive oral semaglutide 25mg (n=205) or placebo (n=102), as an adjunct to lifestyle intervention. The coprimary endpoints were the relative change in ...

A decision is expected in the fourth quarter of 2025.

Novo Nordisk (NVO) stock in focus as oral Wegovy is accepted for FDA review for chronic weight management. Read more here.

The company's experimental once-daily version will become the first oral GLP-1 for chronic weight management, if approved.

Health Canada begins a priority review of semaglutide 2.4 mg, a weekly treatment by Novo Nordisk for MASH, a liver disease ...

Ozempic’s popularity for weight loss is growing, and according to a 2024 survey from KFF, about two in five adults in the US ...

BRITS could soon be able to get Ozempic-style fat jabs from high street pharmacies, according to reports. Drugs like Wegovy ...

The WHO's conditional recommendation will be officially released in August, as part of new guidelines on treating obesity. It is also working on separate guidelines for children and adolescents.

Keeping up with the GLP-1 area is a full-time job by itself. First off, you have the recent development that these drugs are ...

Health service to make medications Mounjaro and Wegovy available after short consultation as part of war on obesity ...

Novo Nordisk's collaboration with telehealth providers offers semaglutide at $499/month, enhancing access for self-paying ...